laurabbook@gmail.com

*February 2022* In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks with Dr. Zosia Piotrowska, Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital in Boston, Mass., about the current and future state of therapies for patients with EGFR mutant lung cancer. Listen here.

*December 2021* NEW YORK – Daiichi Sankyo and AstraZeneca on Thursday said that the first patient with HER2-mutant advanced non-small cell lung cancer has received treatment in a Phase III trial comparing their antibody-drug conjugate trastuzumab deruxtecan (Enhertu) against an immunotherapy-chemotherapy combination in the first-line setting. The DESTINY-Lung04 trial is evaluating trastuzumab…

*December 2021* Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to patritumab deruxtecan (HER3-DXd), a potential first-in-class HER3 directed antibody drug conjugate (ADC), for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC)…

*September 2021* Note: This is a deep dive into the different types of EGFR NSCLC and  how EGFR TKIs (targeted therapies) work, how resistance occurs, and the mechanisms of drug resistance and therapeutic strategies. It's a good article to keep in your back pocket for reference after progression on osimertinib…

*December 2021* How people from different ethnic populations respond differently to treatments for a type of lung cancer called non-small cell lung cancer (also known as NSCLC). EGFR tyrosine kinase inhibitors (often shortened to EGFR TKI treatments) are a form of treatment for NSCLC called EGFR mutation-positive NSCLC. There are currently…

*January 2022* A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC WSD0922-FU for the Treatment…

*August 2020* The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients…